MedTrace Logo

Trivalent Salmonella Conjugate Vaccine (TSCV)

NCT05784701 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2025-05-02

No results posted yet for this study

Summary

This is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV). The trial will proceed from adults, to children, to toddlers, and then to infants.

Conditions

  • Trivalent Salmonella Conjugate Vaccine (TSCV)

Interventions

DRUG

TSCV (Full-strength)

TSCV (Full-strength)

DRUG

TSCV (Half-strength)

TSCV (Half-strength)

DRUG

Typbar-TCV

Typbar-TCV

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Bharat Biotech International

    collaborator UNKNOWN

  • Wellcome Trust

    collaborator OTHER

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Miligritos Tapia, MD · University of Maryland Center for Vaccine Development

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Weeks
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-05
Primary Completion
2027-01-05
Completion
2027-12-30
FDA Drug
Yes

Countries

  • Mali

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05784701 on ClinicalTrials.gov